Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
Details : Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Product Name : KIT2014
Product Type : Peptide
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing